Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/cid/ciaa524 http://scihub22266oqcxt.onion/10.1093/cid/ciaa524 32361747!7197597!32361747     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Infect+Dis 2020 ; 71 (10): 2736-2743 Nephropedia Template TP {{tp|p=32361747|t=2020. Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect?|pdf=|usr=}}{{32361747}} gab.com Text Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect JO: Clin Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32361747 #FOAvip Coronavirus disease 2019 (COVID-19) arose at a time of great concern about antimicrobial resistance (AMR). No studies have specifically assessed COVID-19-associated superinfections or AMR. Based on limited data from case series, it is reasonable to anticipate that an appreciable minority of patients with severe COVID-19 will develop superinfections, most commonly pneumonia due to nosocomial bacteria and Aspergillus. Microbiology and AMR patterns are likely to reflect institutional ecology. Broad-spectrum antimicrobial use is likely to be widespread among hospitalized patients, both as directed and empiric therapy. Stewardship will have a crucial role in limiting unnecessary antimicrobial use and AMR. Congressional COVID-19 relief bills are considering antimicrobial reimbursement reforms and antimicrobial subscription models, but it is unclear if these will be included in final legislation. Prospective studies on COVID-19 superinfections are needed, data from which can inform rational antimicrobial treatment and stewardship strategies, and models for market reform and sustainable drug development. Twit Text FOAVip Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect ????Clin Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32361747 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32361747 #FOAvip English Wikipedia <ref>{{Cite pmid|32361747}}</ref> Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect? #MMPMID32361747 Clancy CJ; Nguyen MH Clin Infect Dis 2020[Dec]; 71 (10): 2736-2743 PMID32361747show ga Coronavirus disease 2019 (COVID-19) arose at a time of great concern about antimicrobial resistance (AMR). No studies have specifically assessed COVID-19-associated superinfections or AMR. Based on limited data from case series, it is reasonable to anticipate that an appreciable minority of patients with severe COVID-19 will develop superinfections, most commonly pneumonia due to nosocomial bacteria and Aspergillus. Microbiology and AMR patterns are likely to reflect institutional ecology. Broad-spectrum antimicrobial use is likely to be widespread among hospitalized patients, both as directed and empiric therapy. Stewardship will have a crucial role in limiting unnecessary antimicrobial use and AMR. Congressional COVID-19 relief bills are considering antimicrobial reimbursement reforms and antimicrobial subscription models, but it is unclear if these will be included in final legislation. Prospective studies on COVID-19 superinfections are needed, data from which can inform rational antimicrobial treatment and stewardship strategies, and models for market reform and sustainable drug development. |*Anti-Infective Agents/therapeutic use[MESH] |*COVID-19[MESH] |*Superinfection/drug therapy[MESH] |Anti-Bacterial Agents/therapeutic use[MESH] |Humans[MESH] |Prospective Studies[MESH]Coronavirus Disease 2019, Superinfections, and Antimicrobial Developme(epmc).pdf DeepDyve Pubget Overpricing